Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 3/20 | 0.44 |
| ▸ | NPY5R | Q15761 | 13/20 | 0.43 |
| ▸ | CCNC | P24863 | 2/20 | 0.40 |
| ▸ | CDK8 | P49336 | 2/20 | 0.40 |
| ▸ | HASPIN | Q8TF76 | 2/20 | 0.40 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL351167 | 1.00 | HSD11B1 (0.44) | HSD11B1NPY5RCCNCCDK8HASPIN | |
| Hydrochloric Acid SCHEMBL350202 | 0.99 | HSD11B1 (0.43) | HSD11B1NPY5RCCNCCDK8HASPIN | |
| SCHEMBL350821 | 0.80 | SIGMAR1 (0.48) | NPY5RSIGMAR1 | |
| SCHEMBL3223126 | 0.80 | SIGMAR1 (0.48) | NPY5RSIGMAR1 | |
| SCHEMBL736674 | 0.79 | CCNC (0.49) | NPY5RCCNCCDK8HASPINCDK19 | |
| Hydrochloric Acid SCHEMBL349643 | 0.79 | SIGMAR1 (0.47) | NPY5RSIGMAR1 | |
| SCHEMBL349938 | 0.79 | CCNC (0.37) | CCNCCDK8HASPINCDK19SIGMAR1 | |
| SCHEMBL15710521 | 0.78 | NPY5R (0.48) | HSD11B1NPY5RSIGMAR1 | |
| SCHEMBL6820764 | 0.78 | NPY5R (0.48) | HSD11B1NPY5RSIGMAR1 | |
| SCHEMBL351041 | 0.76 | CYP1A2 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1756063-A4 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORP (US) | 2009-03-25 | — | — | EP | claimed |
| EP-1756063-A1 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | Incyte Corporation (US) | 2007-02-28 | — | — | EP | claimed |
| WO-2005110992-A1 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2005-11-24 | — | — | WO | claimed |
| EP-1758582-A4 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORP (US) | 2008-01-09 | — | — | EP | disclosed |
| EP-1758582-A1 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | Incyte Corporation (US) | 2007-03-07 | — | — | EP | disclosed |
| US-20060009471-A1 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2006-01-12 | — | — | US | disclosed |
| WO-2006002349-A1 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2006-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060009471-A1 | Amido compounds and their use as pharmaceuticals | HSD11B1, CYP11B1, HSD11B2 | HSD11B1 1/4885NPY5R 642/4885CCNC 4446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.